上海奥浦迈生物科技股份有限公司 独立董事陶化安对本议案投弃权票，投票理由为"对于本次并购的必要性，本 人认为公司现阶段不具有并购的必要性，持否定意见，因此投出反对票；对于本次 并购的合理性，本人不发表意见，因此投出弃权票"。 上述议案尚需提交公司董事会审议。 二、审议通过了《关于修订<上海奥浦迈生物科技股份有限公司发行股份及支付 现金购买资产并募集配套资金报告书（草案）>及其摘要的议案》 议案内容：鉴于本次交易审计基准日更新至 2025 年 6 月 30 日，公司根据《证 券法》以及《上市公司重大资产重组管理办法》等相关法律法规及其他规范性文件 要求对《上海奥浦迈生物科技股份有限公司发行股份及支付现金购买资产并募集配 套资金报告书（草案）》及其摘要的相关内容进行修订更新。 一、审议通过了《关于本次交易相关的标的公司经审计的加期财务报告及上市 公司经审阅的备考财务报告的议案》 议案内容：鉴于本次交易审计基准日更新至 2025 年 6 月 30 日，根据《上市公 司重大资产重组管理办法》及相关规范性文件的规定，公司就本次交易聘请符合《证 券法》规定的立信会计师事务所（特殊普通合伙）出具了《澎立生物医药技术（上 海 ...

Group 1 - Aopumai (SH 688293) announced on September 24 that its 14th meeting of the second board of directors was held, reviewing financial reports related to a recent transaction [1] - For the fiscal year 2024, Aopumai's revenue composition is as follows: 82.16% from culture media business, 17.68% from CDMO services, and 0.16% from leasing income [1] - As of the report date, Aopumai's market capitalization stands at 6.6 billion yuan [1] Group 2 - On the anniversary of September 24, the total market capitalization of A-shares exceeded 116 trillion yuan, indicating significant changes in the Chinese capital market [1]

奥浦迈公告，上海奥浦迈生物科技股份有限公司拟通过发行股份及支付现金方式购买澎立生物医药技术 （上海）股份有限公司100.00%股权，并向不超过35名特定投资者发行股票募集配套资金本次交易事项 尚需满足多项条件后方可实施，包括但不限于上交所审核通过，中国证券监督管理委员会同意注册等， 本次交易最终能否取得上述批准和注册，以及最终取得审核通过和同意注册的时间均存在不确定性。 ...

证券代码：688293 证券简称：奥浦迈 公告编号：2025-084 上海奥浦迈生物科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （二）股东大会召开的地点：上海市浦东新区紫萍路 908 弄 28 号楼上海奥浦迈 生物科技股份有限公司 五楼公司会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其 持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 83 | | --- | --- | | 普通股股东人数 | 83 | | 2、出席会议的股东所持有的表决权数量 | 55,864,823 | | 普通股股东所持有表决权数量 | 55,864,823 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 49.1989 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 49.1989 | （四）表决方式是否符合《公司法》及公司章程的规定，大 ...

FANGDA PARTNERS http://www.fangdalaw.com 中国上海市石门一路 288 号 电子邮件 E-mail: email@fangdalaw.com 兴业太古汇香港兴业中心二座 24 楼 电 话 Tel.: +86-21-2208 1166 邮政编码：200041 传 真 Fax.: +86-21-5298 5599 24/F, HKRI Centre Two HKRI Taikoo Hui 288 Shi Men Yi Road Shanghai, PRC 200041 上海市方达律师事务所 关于上海奥浦迈生物科技股份有限公司 2025 年第二次临时股东大会的法律意见书 致：上海奥浦迈生物科技股份有限公司 上海市方达律师事务所（以下简称"本所"）是具有中华人民共和国境内法律 执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席上海奥浦迈 生物科技股份有限公司（以下简称"公司"）2025 年第二次临时股东大会（以下 简称"本次股东大会"），并就本次股东大会的召集和召开程序、参与表决和召集 会议人员的资格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中 ...

Market Overview - The biopharmaceutical sector experienced a slight increase of 0.0% on September 12, with Aopumai leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up by 0.22%, while the Shenzhen Component Index closed at 12996.38, up by 0.13% [1] Top Gainers in Biopharmaceutical Sector - Aopumai (688293) closed at 54.00, with a rise of 4.73% and a trading volume of 20,300 lots, totaling a transaction value of 103 million [1] - Kexing Pharmaceutical (688136) closed at 42.28, increasing by 3.45% with a trading volume of 47,400 lots, amounting to 197 million [1] - Sanofi (688336) closed at 57.07, up by 3.39% with a trading volume of 52,600 lots, totaling 294 million [1] - Tibet Pharmaceutical (600211) closed at 56.60, rising by 3.38% with a trading volume of 93,300 lots, totaling 510 million [1] - Wenqu Pharmaceutical (688488) closed at 16.00, increasing by 2.83% with a trading volume of 86,300 lots, amounting to 134 million [1] Top Decliners in Biopharmaceutical Sector - Rongchang Biopharmaceutical (688331) closed at 107.22, down by 2.68% with a trading volume of 56,400 lots, totaling 611 million [2] - Wanze Shares (000534) closed at 16.02, decreasing by 2.61% with a trading volume of 135,500 lots, amounting to 218 million [2] - Kangtai Biopharmaceutical (300601) closed at 18.63, down by 1.48% with a trading volume of 156,700 lots, totaling 292 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 310 million from institutional investors, while retail investors experienced a net inflow of 132 million [2] - Notable net inflows from retail investors were observed in Kanghua Biological (300841) with 94.86 million, and Xizang Pharmaceutical (600211) with 49.76 million [3] - Conversely, significant net outflows were noted in Rongchang Biopharmaceutical (688331) with 17.13 million and Aopumai (688293) with 18.19 million from retail investors [3]

Core Viewpoint - Shanghai Dongzhou Asset Appraisal Co., Ltd. has responded to the inquiry letter regarding the asset purchase and fundraising by Shanghai Aopumai Biotechnology Co., Ltd., detailing the evaluation of the target company, Pengli Bio, with a final transaction price of 1,450.507 million yuan [1] Evaluation Methodology - The evaluation utilized both the income approach and market approach to assess the total equity value of the target company, with the income approach yielding a value of 1,452 million yuan and a value increase rate of 56.62%, while the market approach provided a value of 1,485 million yuan with a 60.18% increase rate [1][2] - The market approach involved comparing the target company with comparable companies based on various operational metrics, and the key parameters used in this evaluation were deemed reasonable [2] Income Approach Advantages - The income approach reflects the target company's future profitability by discounting expected cash flows, which is considered more reliable than the market approach due to the unique operational characteristics of each company and the volatility of market prices [3] - The target company has established a stable delivery system with over 1,800 disease animal models, indicating a solid operational foundation and growth potential [3] Industry Context - The recent valuation differs significantly from previous capital increases due to changes in the biopharmaceutical CRO industry, which saw inflated valuations in early 2022 but has since faced a slowdown in investment and increased competition [4] - The previous capital increase in March 2022 valued the company at 3.22 billion yuan, and the current evaluation reflects the industry's downward trend [4] Revenue and Cost Projections - Revenue forecasts for various segments are considered cautious yet achievable, with the pharmacodynamics evaluation business expected to grow faster than the industry average due to the company's competitive advantages and strategic initiatives [5] - Cost and expense forecasts are comprehensive, with reasonable assumptions regarding gross margins and operating expenses compared to industry peers [5][6] Capital Expenditure and Working Capital - Future capital expenditures are projected to be reasonable, including both renewal and expansion investments, while working capital calculations account for changes in business operations [7] - The discount rate used in the evaluation is within the range of comparable cases, reflecting the specific risks faced by the target company [7] Asset Treatment and Performance Coverage - Surplus assets are treated as working capital, aligning with industry practices, and the classification of non-operating assets is deemed reasonable [8] - The target company achieved 45.38% of its projected revenue and 45.80% of its projected net profit for the first half of 2025, indicating a strong likelihood of meeting future performance targets [9] - The projected compound annual growth rate for net profit from 2025 to 2029 is 20.29%, slightly above the industry average, supporting the reasonableness of the evaluation [9]

经中国证券监督管理委员会《关于同意上海奥浦迈生物科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2022〕1232 号）核准，上海奥浦迈生 物科技股份有限公司（以下简称"奥浦迈"、"上市公司"、"公司"或"发行人"） 首次公开发行人民币普通股（A 股）2,049.5082 万股，每股面值人民币 1 元，发 行价格为每股人民币 80.20 元，募集资金总额为人民币 1,643,705,576.40 元，扣 除发行费用后实际募集资金净额为人民币 1,510,944,779.75 元。本次发行证券已 于 2022 年 9 月 2 日在上海证券交易所上市。国泰海通证券股份有限公司（以下 简称"保荐机构"或"国泰海通"）担任其持续督导保荐机构，持续督导期间为 2022 年 9 月 2 日至 2025 年 12 月 31 日。 国泰海通证券股份有限公司 关于上海奥浦迈生物科技股份有限公司 2025 年半年度持续督导跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：奥浦迈 | | --- | --- | | 保荐代表人姓名：靳宇辰、王冰 | 被保荐公司代码：688293.SH | 重大事项 ...

Group 1 - The core viewpoint of the news is that Aopumai's stock price has decreased by 5.05%, currently trading at 50.37 CNY per share, with a total market capitalization of 5.719 billion CNY [1] - Aopumai Biotechnology Co., Ltd. was established on November 27, 2013, and went public on September 2, 2022. The company specializes in cell culture products and services, with revenue composition being 87.34% from products, 12.53% from services, and 0.13% from other sources [1] - The trading volume for Aopumai was 64.8416 million CNY, with a turnover rate of 1.10% [1] Group 2 - Among Aopumai's top ten circulating shareholders, a fund under ICBC Credit Suisse Asset Management has increased its holdings by 1.2508 million shares, totaling 2.9001 million shares, which represents 3.75% of the circulating shares [2] - The fund, ICBC Credit Suisse Frontier Medical Stock A (001717), has a current scale of 9.33 billion CNY and has achieved a year-to-date return of 41.51%, ranking 537 out of 4222 in its category [2] - The fund manager, Zhao Bei, has a tenure of nearly 11 years, with the fund's best return during this period being 275.3% and the worst being -24.35% [2]

Core Points - The company announced a cash dividend of CNY 0.23000 per share for the 2025 semi-annual profit distribution [2][4] - The total cash dividend distribution amounts to CNY 26,116,213.42 (including tax) based on a total share capital of 113,548,754 shares [4][10] - The profit distribution plan was approved at the annual general meeting held on May 9, 2025 [2] Distribution Plan - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, after the market closes on the registration date [3][4] - Shareholders who have completed designated transactions can receive their cash dividends at their designated securities business department on the distribution date [4][6] - For shareholders who have not completed designated transactions, the dividends will be held by the China Securities Depository and Clearing Corporation until the designated transaction is completed [4] Taxation Details - For individual shareholders and securities investment funds holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of CNY 0.23000 per share [7][8] - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution; tax will be calculated and withheld upon the transfer of shares [7][8] - The actual cash dividend for shares held for less than one month is subject to a 20% tax rate, resulting in a net distribution of CNY 0.18400 per share [8][9] Additional Information - The company will not withhold corporate income tax for other corporate shareholders; they are responsible for self-reporting and paying taxes on their cash dividends [10] - For qualified foreign institutional investors (QFII), a 10% corporate income tax will be withheld, resulting in a net cash dividend of CNY 0.20700 per share [9]